title: A network meta-analysis on randomized trials focusing on the preventive effect of statins on contrast-induced nephropathy.
abstract: Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose), rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive. Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.
authors.affiliation: Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy.
authors.forename: Mariangela
authors.initials: M
authors.lastname: Peruzzi
authors.affiliation: Department of Cardiovascular Sciences, European Hospital, 00149 Rome, Italy.
authors.forename: Leonardo
authors.initials: L
authors.lastname: De Luca
authors.affiliation: Department of Radiology, Copenhagen University Hospital, 2100 Herlev, Denmark.
authors.forename: Henrik S
authors.initials: HS
authors.lastname: Thomsen
authors.affiliation: Division of Cardiology, Policlinico Casilino, 00169 Rome, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Romagnoli
authors.affiliation: Division of Cardiology, University of Turin, 10126 Turin, Italy.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: D'Ascenzo
authors.affiliation: Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, 00185 Rome, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Mancone
authors.affiliation: Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, 00185 Rome, Italy.
authors.forename: Gennaro
authors.initials: G
authors.lastname: Sardella
authors.affiliation: Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences, Sapienza University of Rome, 00185 Rome, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Lucisano
authors.affiliation: VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
authors.forename: Antonio
authors.initials: A
authors.lastname: Abbate
authors.affiliation: Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy ; Department of Angiocardioneurology, IRCCS Neuromed, 86077 Pozzilli, Italy.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Frati
authors.affiliation: Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy ; VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Biondi-Zoccai
mesh_terms: D016001:Confidence Intervals; D003287:Contrast Media / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012307:Risk Factors
chemical_list: D003287:Contrast Media; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors